Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Xbrane Biopharma AB: Notice of extra general meeting in Xbrane Biopharma AB

2018-03-16 globenewswire
The shareholders of Xbrane Biopharma AB, reg. no. 556749-2375, (the "Company"), are hereby convened to an extra general meeting to be held on Tuesday 3 April 2018, at 17.30 p.m. at Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm. The doors to the meeting will open at 17.00 p.m. (72-0)

Xbrane Biopharma AB: Kallelse till extra bolagsstämma i Xbrane Biopharma AB

2018-03-16 globenewswire
Aktieägarna i Xbrane Biopharma AB, org. nr 556749-2375, ("Bolaget") kallas härmed till extra bolagsstämma tisdagen den 3 april 2018 kl. 17.30 i Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm. Entrén till stämmolokalen öppnas klockan 17.00. (72-0)

Xbrane Biopharma: Kommentar till kallelse till extra bolagsstämma

2018-03-16 globenewswire
Xbrane Biopharma: Kommentar till kallelse till extra bolagsstämma Xbrane Biopharma kallar härmed till extra bolagsstämma tisdagen den 3 april 2018 kl. 17.30 i Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm. Anledningen till kallelsen är att Serendipity Group som äger 11,47% av aktierna i Xbrane föreslår val av ny styrelseordförande samt att erbjuda styrelsen att teckna aktier och teckningsoptioner i bolaget. (72-0)

Xbrane Biopharma: Comment to call for an extraordinary general meeting

2018-03-16 globenewswire
Xbrane Biopharma hereby calls for an extraordinary general meeting on Tuesday, April 3, 2018 at. 17.30 in Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm. The reason for the call for extraordinary general meeting is that Serendipity Group, which owns 11.47% of the shares in Xbrane, proposes to elect a new Chairman of the Board and to offer the Board of Directors the option to subscribe for shares and warrants in the company. (72-0)

U.S. Biotech/Pharma Sector Daily Observations Letter: March 15, 2018

2018-03-16 seekingalpha
The small pullback in the U.S. biotechnology indexes (IBB) (XBI) after a run-up from the recent correction lows looks almost complete and we expect the uptrend to resume soon. (143-0)

Semaglutide Can Prove To Be A Very Profitable Drug For Novo Nordisk In Future Years

2018-03-09 seekingalpha
Lately, Novo Nordisk’s (NVO) oral semaglutide therapy has been in the news, especially after the investigational drug demonstrated favorable results in the PIONEER 1 program related to reduction of blood sugar as well as body weight for type 2 diabetes patients. While the readout from nine more PIONEER programs is anticipated in 2018 and NDA for this drug is planned for 2019, oral semaglutide has already sent chills in the minds of Eli Lilly’s (LLY) investors. (125-0)

Armo BioSciences: Analysis And Valuation Of Recent Immune-Oncology IPO

2018-02-22 seekingalpha
Armo BioSciences is a Silicon Valley-based immune-oncology company that recently launched its $128M IPO on Nasdaq. (88-0)

U.S. Biotech/Pharma Sector Daily Observations Letter: February 5, 2018

2018-02-06 seekingalpha
The selloff accelerated Monday as the stop losses got triggered after breaking 50-DMA for S&P 500 index. On the other hand, there was some indication, the 10-year yield started declining and Treasury bonds spiked after reversing their downward course towards the last hour of trading. Emini futures hit the 200-DMA after hours - another critical support. (97-1)

'Millennial Millions' - A DGI Portfolio Update

2017-12-21 seekingalpha
We started our daughter’s “Millennial Millions” DGI portfolio in 2015; it is now comprised of 38 positions. (349-0)

Grounds for concern over firms that snap up freeholds

He lives in a 16th-century moated manor house in Norfolk, with a 4,500 acre estate full of grey partridges and a penchant for collecting Old Masters. Earlier this year he was reported to have sold a prized collection of drawings by artists such as Michelangelo, Rubens and Goya to the Getty Museum for $100m. (76-0)

Your Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing Agreement

2017-12-15 seekingalpha
Today we will discuss an article on Conatus Pharmaceuticals (CNAT) by Stephen Ayers, titled, “Conatus: Likely To Dash Ahead Of NASH Data.” (163-7)

How Did Bristol-Myers Squibb Perform in 3Q17?

2017-11-29 marketrealist
In 3Q17, Bristol-Myers Squibb (BMY) reported revenues of $5.3 billion, a ~7% increase on a year-over-year (or YoY) basis and 2% growth on a quarter-over-quarter basis. Bristol-Myers Squibb reported revenues of $14.2 billion in the first nine months of 2017 compared to $12.9 billion in the corresponding period of 2016. (72-0)

Bristol-Myers Squibb (BMY) Presents at 2017 Evercore ISI Biopharma Catalyst/Deep Dive Conference (Transcript)

2017-11-29 seekingalpha
Okay. Great. Well, thank you all for joining us. Pleasure to have Fouad from Bristol-Myers' Head of Oncology Development join us. Fouad, thank you for joining us. Thank you, John for being here. I also said John should be here, but John like to keep it low-key right now, but we'll keep coming back to you. (75-0)

Biotech Investment and Deal-making are Front and Center at #BIOCEO18

The business of making life-saving treatments is fraught with setbacks, challenges and failures. Along the way, new discoveries may pivot searches in new directions. Failures are not necessarily the end of the journey, and with each setback, new data is added to future research. Consider the recent CAR-T cell immunotherapy approvals by the FDA, ushering in a new era of exciting new medicines. These therapies have been in development for a least two decades requiring sustained infusions of cash and a solid commitment to bring concept to reality. (337-0)

Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

2017-11-29 zacks
It was a relatively slow week given the Thanksgiving break. Key developments this week include Biogen’s (BIIB - Free Report) deal with Alkermes (ALKS - Free Report) and Regeneron’s (REGN - Free Report) disappointing data on Eylea. Recap of the Week’s Most Important Stories Biogen Inks Deal with Alkermes for MS Drug: Biogen, a key player in the multiple sclerosis (“MS”) market, has signed up with Alkermes for the worldwide development and commercialization of ALKS 8700. (302-0)

CUSIP: 110122908